Lanean...
Advances in the treatment of newly diagnosed glioblastoma
Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and thes...
Gorde:
| Argitaratua izan da: | BMC Med |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4673777/ https://ncbi.nlm.nih.gov/pubmed/26646075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0536-8 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|